<- Go Home
hVIVO plc
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, it provides preclinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
Market Cap
GBP 73.1M
Volume
3.2M
Cash and Equivalents
GBP 44.2M
EBITDA
GBP 14.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 16.4M
Profit Margin
24.79%
52 Week High
GBP 0.31
52 Week Low
GBP 0.07
Dividend
1.86%
Price / Book Value
1.64
Price / Earnings
6.94
Price / Tangible Book Value
1.88
Enterprise Value
GBP 41.9M
Enterprise Value / EBITDA
2.56
Operating Income
GBP 12.9M
Return on Equity
26.97%
Return on Assets
9.34
Cash and Short Term Investments
GBP 44.2M
Debt
GBP 12.9M
Equity
GBP 44.7M
Revenue
GBP 66.2M
Unlevered FCF
GBP 3.5M
Sector
Life Sciences Tools and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium